Gustave Roussy and LXRepair announce a partnership for personalized radiotherapy of cancer

21 october 2021

Gustave Roussy and LXRepair announce a partnership for personalized radiotherapy of cancer

PLXRepair, a pioneer in personalized radiotherapy with functional assays measuring DNA repair to predict treatment response, with a clinical proof-of-concept of radiotoxicity prediction in breast and prostate cancer, and Gustave Roussy, Europe's leading cancer center, announced today the launch of a joint laboratory to improve the personalization of radiotherapy.

Good to know 12

Newsletter Good to Know

Gustave Roussy's medical-scientific programmes

Gustave Roussy's medical-scientific programmes

As part of its "Gustave Roussy 2030" strategic plan, the Institute has identified ten flagship programmes aimed at specifically transforming cancer care through research. These programmes are based on the clinical, translational and fundamental research activities carried out by the Gustave Roussy teams.
 

Consultation hématurie

L'hématurie désigne la présence de sang dans les urines (urines rouges) et n’est jamais normale. Plusieurs causes peuvent être à son origine, mais elle peut parfois signaler la présence de cellules tumorales au sein de l’appareil urinaire, en particulier au sein de la vessie. C'est pourquoi il est important d’établir rapidement un diagnostic, afin de traiter une éventuelle tumeur le plus tôt possible. 

Bioinformatics core facility - major publications

Bioinformatics core facility - Major publications

  • Nguyen-Khac, F. et al. Acquisition of TCF3 and CCND3 Mutations and Transformation to Burkitt Lymphoma in a Case of B-Cell Prolymphocytic Leukemia. Hemasphere 5, e563 (2021).
  • Mazzi, S. et al. Dual role of EZH2 on megakaryocyte differentiation. Blood blood.2019004638 (2021) doi:10.1182/blood.2019004638.
  • Kuksin, M. et al. Applications of single-cell and bulk RNA sequencing in onco-immunology. Eur J Cancer 149, 193–210 (2021).

SEngine Precision Medicine and Gustave Roussy Announce Plan to Launch PARIS® Test in Europe

Villejuif, 05 october 2021

SEngine Precision Medicine and Gustave Roussy Announce Plan to Launch PARIS® Test in Europe

Prospective joint venture will accelerate precision medicine in Europe by harnessing innovations in high-throughput drug testing, 3D tumor cell culture, and AI analytics established at SEngine Precision Medicine to identify the best personalized therapeutic matches for patients

CSET 3308

Les tumeurs neuroendocrines (TNE) sont des cancers d’évolution habituellement lente qui, pour se développer et augmenter en taille, vont avoir besoin de vaisseaux sanguins pour assurer leur croissance. Les thérapies ciblées anti angiogéniques ont montré leur efficacité dans les TNE et dans d’autre cancer en ciblant ces vaisseaux sanguins tumoraux.

Pages